Aditxt subsidiary Adimune reports positive preclinical data for ADI-100; clinical trials planned in Germany and US

Aditxt, Inc.

Completed toxicology, bio-distribution, persistence, and antibody formation studies for ADI-100 with no safety flags.
Ex vivo data from human patient cells showed ADI-100 down-regulates anti-GAD immune activity, supporting clinical advancement.
IP portfolio includes 130-150 patents/applications protecting the ADI platform as a tolerance delivery system.
Clinical studies planned: psoriasis and type 1 diabetes in Germany; stiff-person syndrome and neurological in US.
ADI-100 aims to restore immune tolerance using apoptotic cells and modified antigen (GAD), not general immune suppression.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.